Aemetis, Inc. (NASDAQ:AMTX – Get Free Report)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.27 and traded as low as $4.65. Aemetis shares last traded at $4.90, with a volume of 467,928 shares changing hands.
Analysts Set New Price Targets
Several research analysts have weighed in on the stock. UBS Group raised shares of Aemetis from a “neutral” rating to a “buy” rating and increased their price target for the company from $2.50 to $10.50 in a report on Wednesday, August 16th. Stifel Nicolaus increased their target price on shares of Aemetis from $9.00 to $10.50 and gave the stock a “buy” rating in a research report on Tuesday, August 22nd. Finally, HC Wainwright restated a “buy” rating and set a $28.00 target price on shares of Aemetis in a research report on Friday, September 15th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.90.
Aemetis Trading Up 1.4 %
Insider Buying and Selling
In related news, Director Naomi Louise Boness sold 15,000 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $5.65, for a total transaction of $84,750.00. Following the sale, the director now owns 16,441 shares in the company, valued at approximately $92,891.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 14.34% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Aemetis
Several large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its stake in shares of Aemetis by 3.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 75,306 shares of the specialty chemicals company’s stock valued at $955,000 after acquiring an additional 2,254 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Aemetis by 16.0% during the first quarter. JPMorgan Chase & Co. now owns 16,362 shares of the specialty chemicals company’s stock worth $208,000 after buying an additional 2,256 shares during the last quarter. Guggenheim Capital LLC raised its stake in Aemetis by 18.7% during the third quarter. Guggenheim Capital LLC now owns 17,879 shares of the specialty chemicals company’s stock worth $110,000 after buying an additional 2,818 shares during the last quarter. Point72 Asset Management L.P. bought a new position in Aemetis during the second quarter worth $25,000. Finally, Tower Research Capital LLC TRC raised its stake in Aemetis by 173.7% during the third quarter. Tower Research Capital LLC TRC now owns 5,586 shares of the specialty chemicals company’s stock worth $34,000 after buying an additional 3,545 shares during the last quarter. Institutional investors own 27.95% of the company’s stock.
Aemetis Company Profile
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products.
- Five stocks we like better than Aemetis
- How to Invest in Communication Stocks
- 3 large caps with red hot RSIs with upside
- What Is Dividend Yield and How Do You Calculate It?
- Johnson Controls International: Nothing but upside for investors
- Consumer Staples Stocks, Explained
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.